Elsevier

Toxicology

Volume 370, 31 August 2016, Pages 94-105
Toxicology

Inhibition of β-catenin signaling by phenobarbital in hepatoma cells in vitro

https://doi.org/10.1016/j.tox.2016.09.018Get rights and content

Abstract

The antiepileptic drug phenobarbital (PB) exerts hepatic effect based on indirect activation of the constitutive androstane receptor (CAR) via inhibition of the epidermal growth factor receptor (EGFR) and the kinase Src. It has furthermore been observed that in mice PB suppresses the growth of hepatocellular carcinoma with overactive signaling through the oncogenic Wnt/β-catenin pathway, thus suggesting an interference of PB with β-catenin signaling. The present work was aimed to characterize effects of PB on β-catenin signaling at different cellular levels and to elucidate molecular details of the interaction of PB and β-catenin in an in vitro system of mouse hepatoma cells. PB efficiently inhibited signaling through β-catenin. This phenomenon was in-depth characterized at the levels of β-catenin protein accumulation and transcriptional activity. Mechanistic analyses revealed that the effect of PB on β-catenin signaling was independent of the activation of CAR and also independent of the cytosolic multi-protein complex responsible for physiological post-translation control of the β-catenin pathway via initiation of β-catenin degradation. Instead, evidence is provided that PB diminishes β-catenin protein production by inhibition of protein synthesis via signal transduction through EGFR and Src. The proposed mechanism is well in agreement with previously published activities of PB at the EGFR and Src-mediated regulation of β-catenin mRNA translation. Inhibition of β-catenin signaling by PB through the proposed mechanism might explain the inhibitory effect of PB on the growth of specific sub-populations of mouse liver tumors. In conclusion, the present data comprehensively characterize the effect of PB on β-catenin signaling in mouse hepatoma cells in vitro and provides mechanistic insight into the molecular processes underlying the observed effect.

Introduction

Phenobarbital (PB) is an antiepileptic drug due to its interference with γ-aminobutyric acid (GABA)-dependent neurotransmission (Macdonald and McLean, 1986). PB is capable of inducing tumors in rodents by a non-genotoxic mechanism via activation of the constitutive androstane receptor (CAR) and also involving cell–cell communication via the gap junction protein connexin 32 (Cx32) (Moennikes et al., 2000, Yamamoto et al., 2004). For a detailed overview of the toxicological properties of PB please refer to IARC (2001). Human relevance of tumorigenicity of PB through CAR activation is subject of an ongoing controversial debate (Braeuning, 2014, Braeuning et al., 2014, Braeuning et al., 2015, Braeuning and Schwarz, 2016, Elcombe et al., 2014, Yamada et al., 2014).

Despite decades of research on PB effects and CAR activation, the mechanism for the indirect activation of CAR by PB had not been elucidated until a few years ago (Mutoh et al., 2013): PB activates CAR via inhibition of the epidermal growth factor receptor (EGFR). This leads to diminished activity of the kinase Src, which in turn impacts on the phosphorylation of RACK1, thus enabling non-phosphorylated RACK1 to activate protein phosphatase 2A (PP2A) leading to dephosphorylation of CAR. Non-phosphorylated CAR then translocates to the nucleus and initiates pleiotropic transcriptional responses related to hepatocyte proliferation, hypertrophy and apoptosis, but also to xenobiotic metabolism and energy homeostasis. Cellular functions of CAR have e.g. been reviewed by Qatanani and Moore (2005) and by Whysner et al. (1996).

While chronic administration of PB to mice promotes the outgrowth of certain particular hepatoma sub-populations under appropriate experimental conditions, other tumor sub-populations, characterized by their individual tumorigenesis-driving genomic mutations and corresponding gene expression profiles, are significantly inhibited by PB in their growth, thus making the substance more a tumor selector than a tumor promoter (Braeuning and Schwarz, 2016): the formation of hepatocellular carcinoma (HCC) driven by pronounced activation of the canonical Wnt/β-catenin signaling pathway is inhibited by PB in a mouse model of hepatic APC (adenomatous polyposis coli protein) deficiency (Braeuning et al., 2016). Canonical Wnt/β-catenin signaling is one of the most prominent oncogenic signaling cascades and frequently activated in human as well as rodent tumors. Genomic alterations in different critical components of the cascade, for example in Ctnnb1 (encoding β-catenin) or Apc (encoding a negative regulator of β-catenin) lead to constitutive activation of the pathway. This contributes to tumor growth by triggering the expression of downstream target genes related to proliferation and tumorigenesis as reviewed by Lustig and Behrens (2003). Physiologically, the activity of the pathway is mainly regulated by post-translational modifications of β-catenin which impact on the degradation of the protein: phosphorylation of β-catenin at residues near the N-terminus by a cytosolic multi-protein complex which consists, amongst others, of APC and glycogen synthase kinase 3β (GSK3β), primes the protein for subsequent proteasomal degradation. This process is blocked by inhibition of GSK3β or the proteasome, or by Ctnnb1 mutations that eliminate the critical phosphorylation sites; inhibition of β-catenin degradation activates the pathway and leads to cytosolic accumulation and nuclear translocation of free, transcriptionally active β-catenin (Lustig and Behrens, 2003). Of note, β-catenin regulation might also occur via altered transcription of the Ctnnb1 gene (Gosens et al., 2010). Interestingly, the HCC from the abovementioned mouse model are defective in β-catenin degradation due to their lack of functional APC, but additionally exhibit strongly increased Ctnnb1 mRNA levels which also seem to contribute to β-catenin activation in this particular tumor type (Braeuning et al., 2016). Another mechanism of regulation is via enhanced translation of Ctnnb1 mRNA, a process which is mediated by Src kinase which phosphorylates the eukaryotic initiation factor 4E via extracellular signal-regulated kinase (ERK)-dependent signaling and thus regulates β-catenin protein levels by altering its synthesis, not its degradation (Karni et al., 2005). Moreover, mouse liver tumors with activated mitogen-activated protein kinase (MAPK)/ERK signaling due to activating mutations in the Ha-ras proto-oncogene upstream of ERK are also efficiently inhibited by PB (Aydinlik et al., 2001, Moennikes et al., 2000).

HCC from the APC-deficient mouse model described above are repressed by PB despite an almost complete lack of CAR expression (Braeuning et al., 2016). Moreover, MAPK-activated mouse liver tumors exhibit reduced expression of CAR, as compared to normal hepatocytes (Jaworski et al., 2007), and react less sensitive to PB stimulation with regard to the induction of CAR target genes related to xenobiotic metabolism (own unpublished data). It thus appears likely that CAR-independent effects mediate at least some of the tumor-inhibitory effects of PB. As tumor growth is driven by specific oncogenic signaling cascades, it appears plausible that PB might interfere with such cellular signal transduction pathways to inhibit the growth of certain tumor sub-populations. Interestingly, data from a recent publication on PB inhibition of calpains, a family of proteases, suggest an inhibition of β-catenin signaling by PB (Groll et al., 2016a).

Therefore, this study was designed to provide an in-depth analysis of the effects of PB on Wnt/β-catenin signaling in mouse hepatoma cells in vitro and to unravel the underlying molecular mechanisms.

Section snippets

Cell culture and treatment

Mouse hepatoma cells from line 70.4 (Groll et al., 2016a, Kress et al., 1992), stably transfected with the 8 x β-catenin/TCF-driven SuperTopFlash (STF) luciferase reporter vector (Braeuning et al., 2007), and a 70.4-derived sub-clone stably transfected with a doxycycline-inducible system for the expression of mutant, constitutively active human β-cateninS33Y (termed “70.4Mo”; Zeller et al., 2012) were cultivated in D-MEM/F12 medium supplemented with 10% fetal calf serum and antibiotics as

Results

In the course of a recent analysis of PB effects on calpain expression and activity it has been reported that PB inhibits β-catenin signaling in mouse hepatoma cells in vitro (Groll et al., 2016a). Neither a comprehensive description nor a mechanistic interpretation of this phenomenon has been published in the literature. It has also recently been shown that the outgrowth of β-catenin-driven HCC is reduced by PB in a mouse model of HCC (Braeuning et al., 2016). This was now followed up in order

Discussion

The present data show that PB inhibits signaling through the oncogenic β-catenin signaling pathway in hepatoma cells. While β-catenin inhibition by PB has been mentioned as a secondary finding in a single previous publication (Groll et al., 2016a), this is the first study which provides an in-depth characterization of the phenomenon and provides insight into the underlying molecular mechanisms.

The inhibitory effect of PB on β-catenin was shown to be independent of the nuclear receptor CAR and

Acknowledgments

The authors thank Johanna Mahr and Elke Zabinsky for expert technical assistance. The gift of Src kinase expression vectors by Dr. R. Lammers (Tübingen, Germany) and of erlotinib by Dr. M. Toulany (Tübingen, Germany) is greatly acknowledged. This work was funded by the German Federal Ministry of Education and Research (BMBF), grant FKZ 0315742 (Virtual Liver).

References (48)

  • N. Bluthgen et al.

    Systems analysis of MAPK signal transduction

    Essays Biochem.

    (2008)
  • N. Bluthgen

    Signaling output: it's all about timing and feedbacks

    Mol. Syst. Biol.

    (2015)
  • A. Braeuning et al.

    Is the question of phenobarbital as potential liver cancer risk factor for humans really resolved?

    Arch. Toxicol.

    (2016)
  • A. Braeuning et al.

    The nuclear factor kappaB inhibitor (E)-2-fluoro-4'-methoxystilbene inhibits firefly luciferase

    Biosci. Rep.

    (2012)
  • A. Braeuning et al.

    Serum components and activated Ha-ras antagonize expression of perivenous marker genes stimulated by beta-catenin signaling in mouse hepatocytes

    FEBS J.

    (2007)
  • A. Braeuning et al.

    Inducibility of drug-metabolizing enzymes by xenobiotics in mice with liver-specific knockout of Ctnnb1

    Drug Metab. Dispos.

    (2009)
  • A. Braeuning et al.

    Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway

    Toxicol. Sci.

    (2011)
  • A. Braeuning et al.

    Phenobarbital-mediated tumor promotion in transgenic mice with humanized CAR and PXR

    Toxicol. Sci.

    (2014)
  • A. Braeuning et al.

    Model systems for understanding mechanisms of nongenotoxic carcinogenesis: response

    Toxicol. Sci.

    (2015)
  • A. Braeuning et al.

    Tumor promotion and inhibition by phenobarbital in livers of conditional Apc-deficient mice

    Arch. Toxicol.

    (2016)
  • A. Braeuning

    Liver cell proliferation and tumor promotion by phenobarbital: relevance for humans?

    Arch. Toxicol.

    (2014)
  • C.R. Elcombe et al.

    Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: a case study with phenobarbital as a model constitutive androstane receptor (CAR) activator

    Crit. Rev. Toxicol.

    (2014)
  • R. Gosens et al.

    De novo synthesis of {beta}-catenin via H-Ras and MEK regulates airway smooth muscle growth

    FASEB J.

    (2010)
  • N. Groll et al.

    A bead-based multiplex sandwich immunoassay to assess the abundance and posttranslational modification state of beta-catenin

    Methods Mol. Biol.

    (2015)
  • Cited by (5)

    • Harnessing drug/radiation interaction through daily routine practice: Leverage medical and methodological point of view (MORSE 02-17 study)

      2018, Radiotherapy and Oncology
      Citation Excerpt :

      Out of the 833 concurrent NACTs, 20 (prescribed to 74 patients, 34.6%) were identified as possible modifiers of cancer biological pathways. Indeed, NACTs identified in the present study were suggested to change the following molecular cancer pathways in preclinical or clinical literature: AKT-mTOR, RAS-MAPK, angiogenesis, apoptosis, Sonic Hedgehog, epithelial to mesenchymal transition, cell survival and proliferation (Fig. 2) [4,25,35,49,6,2,52,20,51,38,10,11,14,18,24,30,39,19,27,34,37,5,13,17,36,43,44,48,50,15,41,46]. Twenty-eight recruiting or published clinical trials investigating the combination of NACTs with radiotherapy were identified (Table 3).

    • Porcine cytochrome 2A19 and 2E1

      2019, Basic and Clinical Pharmacology and Toxicology
    View full text